Business Context and Reporting Period
This Form 8-K Current Report from Cartesian Therapeutics, Inc. (RNAC) covers events occurring on September 20, 2024, and September 25, 2024. The filing details the conclusion of a Special Meeting of Stockholders and the subsequent automatic conversion of the Company's Series B Non-Voting Convertible Preferred Stock into Common Stock.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance and capital structure changes.
- Outstanding Shares: Following the conversion, 23,893,525 shares of Common Stock are issued and outstanding.
- Stock Class: Common Stock (Par Value $0.0001) trading on The Nasdaq Stock Market LLC.
Material Changes
The primary material change is the capital structure adjustment resulting from the Automatic Conversion of Series B Preferred Stock.
- Stockholder Approval: On September 20, 2024, stockholders approved the issuance of Common Stock upon conversion of Series B Preferred Stock.
- Conversion Execution: The Automatic Conversion occurred on September 25, 2024, at 5:00 p.m. Eastern Time, pursuant to the Certificate of Designation.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, operational outlook, risks, contingencies, or unusual items. The document is strictly a notification of the completed stock conversion event.
Investor Verification Checklist
- Verify the updated total share count of 23,893,525 shares of Common Stock outstanding.
- Confirm the elimination of Series B Non-Voting Convertible Preferred Stock from the capital structure.
- Review the Certificate of Designation for any remaining terms related to the converted shares.